Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening
Primary Purpose
Hip Arthrosis
Status
Completed
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Clodronate
Saline
Sponsored by
About this trial
This is an interventional treatment trial for Hip Arthrosis focused on measuring RSA, DXA, Bisphosphonates, Migration of stem, Aseptic loosening of prosthesis
Eligibility Criteria
Inclusion Criteria:
- hip arthrosis and
- a primary THA was planned
Exclusion Criteria:
- renal insufficiency
- hypercalcemia
- malignant tumors
- contemporaneously treatment with another bisphosphonate or aminoglycoside
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Clodronate
Saline
Arm Description
1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
Outcomes
Primary Outcome Measures
Maximal total point motion (MTPM) - migration of the femoral stem
It represents the length of the translation vector of the point in a rigid body that has the greatest motion. It can only have positive values, and is not normally distributed. The reason for using MTPM is that in many cases, motion implies a biological effect of some kind and this effect is liable to be greatest at the point of maximum motion. The parameter has been measured by RSA-methods, which is an accurate method of determining the migration and wear of orthopaedic implants: it determine the precise location of two distinct objects relative to each other in three dimension such as the relative position of the femoral component and the proximal femur. In radiostereometric analysis the position in space of the original object is reconstructed from a two dimensional x-ray film using tantalum beads. Movement between segments is then calculated by localizing each segment in a coordinate system. Lower values represent a better outcome.
Secondary Outcome Measures
Bone mineral density (BMD) in 7 Gruen zones
BMD was measured by dual-energy X-ray absorptiometry, DXA. In clinical use, precision errors are < 5 %. To evaluate the horizontal linear distribution of the BMD, seven Gruen zones, peri-prosthetic sub-regions of interest, ROI (region of interest) were calculated by the software on the anteroposterior view of the proximal femur. The value of BMD is g/cm2 and it estimates the strength of the bone. Higher values/lesser decrease in values represent a better outcome.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03803839
Brief Title
Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening
Official Title
Could the Intra-operative Clodronate Rinsing Improve the Integration of the Femoral Stem in a Prospective, Double-blinded, Randomized, Placebo-controlled Clinical RSA-study
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
March 26, 2004 (Actual)
Primary Completion Date
March 12, 2014 (Actual)
Study Completion Date
March 12, 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oulu
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Periprosthetic bone-loss after total hip arthroplasty (THA), detected as an early migration of the prosthesis, may predict later loosening. The investigators hypothesized that by reducing bone resorption after THA with bisphosphonates, it might be possible to achieve better early fixation of the implant.
Nineteen patients suffering arthrosis were recruited to a prospective, double-blinded, randomized, placebo-controlled clinical pilot trial. Patients were operated with an uncemented Bimetric stem with tantalum markers, the acetabular cup and liner were chosen by the surgeon. The femoral proximal intramedullary canal was rinsed with 1mM (millimole) clodronate, that was done by adding the clodronate to the 1000 ml 0.9% NaCl (sodium chloride) in nine patients and rinsing solution was the pure 0.9% NaCl for 10 patients. These rinsing packages were labeled only with the code from the pharmacy of the hospital. These patients were followed for two years using radiostereometric analysis (RSA), dual energy x-ray absorptiometry (DXA) and the Harris hip score (HHS).
The purpose of the investigator's study was to examine whether the local intraoperative administration of clodronate could reduce periprosthetic bone loss and further stem migration after primary THA.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Arthrosis
Keywords
RSA, DXA, Bisphosphonates, Migration of stem, Aseptic loosening of prosthesis
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Model Description
In this prospective, double-blinded, randomized, placebo-controlled clinical trial with two years follow-up period the investigators rinsed the proximal intramedullary cavity of the femur with either clodronate (60 mg clodronate in 1000 ml saline) or saline (1000 ml saline) prior to the application of the femoral stem.
Masking
ParticipantCare ProviderInvestigator
Masking Description
Patients were randomized into two treatment groups; either the clodronate or a placebo group. All patients, surgeons and other personnel in the operating theatre were blinded as to the patients' study group.
Allocation
Randomized
Enrollment
19 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Clodronate
Arm Type
Active Comparator
Arm Description
1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
Intervention Type
Drug
Intervention Name(s)
Clodronate
Intervention Type
Drug
Intervention Name(s)
Saline
Primary Outcome Measure Information:
Title
Maximal total point motion (MTPM) - migration of the femoral stem
Description
It represents the length of the translation vector of the point in a rigid body that has the greatest motion. It can only have positive values, and is not normally distributed. The reason for using MTPM is that in many cases, motion implies a biological effect of some kind and this effect is liable to be greatest at the point of maximum motion. The parameter has been measured by RSA-methods, which is an accurate method of determining the migration and wear of orthopaedic implants: it determine the precise location of two distinct objects relative to each other in three dimension such as the relative position of the femoral component and the proximal femur. In radiostereometric analysis the position in space of the original object is reconstructed from a two dimensional x-ray film using tantalum beads. Movement between segments is then calculated by localizing each segment in a coordinate system. Lower values represent a better outcome.
Time Frame
0 to 24 months
Secondary Outcome Measure Information:
Title
Bone mineral density (BMD) in 7 Gruen zones
Description
BMD was measured by dual-energy X-ray absorptiometry, DXA. In clinical use, precision errors are < 5 %. To evaluate the horizontal linear distribution of the BMD, seven Gruen zones, peri-prosthetic sub-regions of interest, ROI (region of interest) were calculated by the software on the anteroposterior view of the proximal femur. The value of BMD is g/cm2 and it estimates the strength of the bone. Higher values/lesser decrease in values represent a better outcome.
Time Frame
0 to 24 months
Other Pre-specified Outcome Measures:
Title
Migration of femoral stem
Description
Subsidence and vertical movement of the femoral stem (scale micrometers), x-, y- and z-translations. Parameters were measured using RSA-methods and the scaling is linear. Lower values represent a better outcome.
Time Frame
0 to 24 months
Title
The maximal (MTPM) maximal total point motion
Description
The maximal MTPM value after 3 months when the expected integration of stem should have happened. Lower values represent a better outcome.
Time Frame
3 to 24 months
Title
Correlation between baseline BMD and the maximal MTPM
Description
This parameters summarize the BMD and RSA values together. The investigators have planned it to evaluate the correlation between the quality of periprosthetic bone in baseline and the migration of femoral stem during 2 years follow-up period between the study groups.
Time Frame
BMD (0 month) - the maximal MTPM 3 to 24 months
Title
Harris Hip Score (HHS)
Description
Harris Hip Score (HHS) is a clinician-based outcome measure, health status scale, that is frequently used to measure the outcome of total hip arthroplasty. It is measured by questionnaire that give points from 0 to 100. Higher values represent a better outcome.
Time Frame
0 to 24 months
10. Eligibility
Sex
All
Maximum Age & Unit of Time
73 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
hip arthrosis and
a primary THA was planned
Exclusion Criteria:
renal insufficiency
hypercalcemia
malignant tumors
contemporaneously treatment with another bisphosphonate or aminoglycoside
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data for all primary and secondary outcome data will be made available.
IPD Sharing Time Frame
Data will be available after submitting the results to the scientific journals and five years after the publication.
IPD Sharing Access Criteria
Data Access requests will be reviewed By an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement.
Learn more about this trial
Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening
We'll reach out to this number within 24 hrs